MicroRNA‚Ä?45 inhibits the malignant phenotypes of gastric carcinoma cells via downregulation of fascin 1 expression
Authors: Zhenjuan Li
Fang Yang
Lunde Zhao
Minghui Xue
Guangyan Li
Journal: Molecular Medicine Reports (2016)
Discipline: CLINICAL MEDICINE
Keywords: MicroRNA; miR-145; tumor suppressor; fascin 1; FSCN1
Affiliations: Department of General Surgery, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China., Department of Gastroenterology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China.

Abstract:  MicroRNA (miR)‚Ä?45 has been demonstrated to act as a tumor suppressor, and deregulation of fascin 1 (FSCN1) has been observed in several types of human malignancy, including gastric carcinoma. However, the molecular mechanism underlying the function of miR‚Ä?45, specifically its targets in gastric carcinoma have yet to be fully elucidated. In the present study, downregulation of miR‚Ä?45 and upregulation of FSCN1 was identified in gastric carcinoma cell lines, compared with normal gastric mucosal epithelial cells. A luciferase reporter assay demonstrated that miR‚Ä?45 was able to bind to the 3'‚Äëuntranslated region of FSCN1 mRNA. Overexpression of miR‚Ä?45 led to a significant decrease in FSCN1 expression levels, whereas knockdown of miR‚Ä?45 resulted in increased FSCN1 expression levels in gastric carcinoma cells. Furthermore, overexpression of miR‚Ä?45 inhibited proliferation, migration and invasion in gastric carcinoma cells. Similar effects were also observed in gastric carcinoma cells transfected with FSCN1 small interfering RNA. In addition, overexpression of FSCN1 reversed the suppressive effects of miR‚Ä?45 upregulation on proliferation, migration and invasion in gastric carcinoma cells, suggesting that FSCN1 is indeed involved in the miR‚Ä?45‚Äëmediated malignant phenotype of gastric carcinoma cells. The present study revealed an anti‚Äëoncogenic role of miR‚Ä?45 in gastric carcinoma via inhibition of FSCN1, and suggested that miR‚Ä?45 may be used for the treatment of gastric carcinoma. 

Retracted: Yes

PubPeer comments:
 Figs 3D, 4D.  A Transwell assay was performed to examine the invasive capacity of AGS cells transfected with miR-145 mimics or FSCN1 siRNA ;  A Transwell assay was performed to determine the invasion capacity of AGS cells transfected with miR-145 mimics or co-transfected with miR-145 mimics and FSCN1 plasmids.  These are versatile panels, appearing in literally dozens of papers by unrelated teams of researchers. Figs 4 and 7 of [Aili, Chen Zhang (2016)] .  Transwell assay was performed to determine the invasive capacity of JJ012 chondrosarcoma cells treated with 5-Aza+PBA, or transfected with NC or miR-10b mimics, respectively ;  A Transwell assay was performed to determine the invasive capacity of JJ012 chondrosarcoma cells transfected with miR-10b mimics, or co-transfected with miR-10b mimics and BDNF plasmid respectively.  Fig 3 C D of [Zhang et al (2016)] .  Transwell assay were performed to examine the migratory and invasive capacities of Saos-2 and U2OS cells transfected with miR-205 mimic or miR-negative control (NC) mimic , and Fig 7C D,  Transwell assay were performed to examine cell migration and invasion of MG63 or U2OS cells transfected with miR-205 mimic, or co-transfected with miR-205 mimic and RUNX2 plasmid .  Also *[above]* Fig 4C from [Lai, Chen Li (2015)] .  a Transwell assay were performed to examine the cell proliferation of AGS cells transfected with miR-133a mimics, miR-133a inhibitor, or co-transfected with miR-133a mimics and FSCN1 plasmid. Control: AGS cells without any transfection. *[below]* Figs 3(B), 6(B) from [Shi et al (2015)] .  Transwell assay was performed to determine the invasive capacity of the Saos-2 and U-2 OS cells transfected with NC scramble miRNA or miR-204 mimics, respectively. Control, Saos-2 and U-2 OS cells without any transfection ...  Transwell assay was performed to determine the invasive capacity of the Saos-2 and U-2 OS cells transfected with Sirt1 siRNA or co-transfected with miR-204 mimics and the Sirt1 plasmid, respectively. Control, Saos-2 and U-2 OS cells without any transfection .  , 
 Retracted [20 January 2022] .  Following the publication of this paper, it was drawn to the Editorsu2019 attention by a concerned reader that certain of the cell apoptotic assay data shown in Figs. 3D and 4D were strikingly similar to data appearing in different form in other articles by different authors. Owing to the fact that the contentious data in the above article had already been published elsewhere, or were already under consideration for publication, prior to its submission to *Molecular Medicine Reports*, the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive any reply. The Editor apologizes to the readership for any inconvenience caused. ,